Development of Rovalpituzumab (Rova-T) Halted in Small Cell Lung Cancer

Rova-T fails to improve outcomes in SCLC.

by Dr. C.H. Weaver M.D. updated 8/2019

The developer of Rovalpituzumab tesirine (Rova-T) halted the key clinical trial in August 2019 because Rova-T failed to meet the trial endpoint demonstrating effectiveness in SCLC. Rova-it is an antibody-drug conjugate that targets a protein associated with the small cell lung cancer cells and is the first biomarker-directed treatment being developed in SCLC. In SCLC, a proportion of the malignant cells display Delta-like protein 3 (DLL3) which is not seen on the surface of normal cells. Rova-T is a combination of an antibody that binds to DLL3 that delivers a toxic substance called tesirine directly to the cancer cells.(1,2)

SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be substantial, long-term survival for patients with SCLC remains poor. Survival in SCLC is no more than 15%, 2 years after diagnosis. These statistics haven’t changed in 40 years and only one drug has been approved to treat recurrent disease.

The results of a clinical trial evaluating 74 patients with SCLC who had failed at least one previous line of therapy were reported at the American Society of Clinical Oncology cancer research meetings in Chicago and initially appeared promising.(2)

Overall 18% of these refractory patients had a confirmed response regardless of the level of DLL3 expression, and the rate among those who were DLL3-high was 39%. A confirmed clinical benefit rate defined as stable disease or better was achieved in 89% of patients who were DLL3-high expressers.

Rova-T will be undergoing additional evaluation in clinical trials alone and in combination with other chemotherapy drugs in the near future.


  2. Rudin CM, Pietanza M, Bauer T, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol 34, 2016 (suppl; abstr LBA8505). Can be accessed at:

Copyright © 2018 CancerConnect. All Rights Reserved.

Comments (1)
No. 1-1

I'm here to testify about the great work Dr Osebor did for me. I have been suffering from (HERPES) disease for the past 5

years and had constant pain, especially in my knees. During the first year,I had faith in God that i would be healed

someday.This disease started circulating all over my body and i have been taking treatment from my doctor, few weeks ago

i came across a testimony of one lady on the internet testifying about a Man called Dr Osebor on how he cured her from

HIV Virus. And she also gave the email address of this man and advise anybody to contact Dr Osebor for help for any kind

of sickness that he would be of help, so I emailed him on ( ) telling him about my (HERPES

Virus) he told me not to worry that i was going to be cured!! Well i never believed it,, well after all the procedures

and remedy given to me by this man few weeks later i started experiencing changes all over me as Dr Osebor assured me

that i will be cured,after some time i went to my doctor to confirmed if i have be finally healed behold it was TRUE, So

friends my advise is if you have such sickness or any other at all you can contact Dr Osebor via email. { }or call or what sapp him on( +2348073245515 )


HIV/AIDS HERPES CANCER ALS cancer eye problem etc.